Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Abstracts & Posters

Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease

key information

source: American Society of Hematology

year: 2015

authors: Jin Han, Santosh L. Saraf, Xu Zhang, Michel Gowhari, Robert E. Molokie, Johara Hassan, Chaher Alhandalous, Jewel Younge, Taimur Abbasi, Roberto F. Machado, Victor R. Gordeuk

summary/abstract:

Background: Pain, the hallmark complication of sickle cell disease (SCD), is largely managed with opioid analgesics in the United States (1, 2). There is a common perception that SCD patients tend to use high dose of opioids chronically (3, 4), but comprehensive data regarding the long-term use of opioids in this patient population is lacking.

Methods: A cohort of 359 adults (age ≥ 18 years old) with the diagnosis of SCD followed at University of Illinois Hospital in FY 2010-2013 was enrolled in a prospective natural history study. An outpatient clinic visit with comprehensive laboratory closest to the enrollment date was selected as the focal point of this report. A total of 140 patients had consistent outpatient follow-up defined as ³4 visits between 6 months prior to and 6 months after this clinic visit (the study period). Pain medication prescribing records, number of hospital admissions, and other clinical variables during the study period were collected and evaluated with descriptive statistics and Spearman correlation.

Results: Among the 140 patients analyzed, 74% took short-acting opioid medications and 31% took long-acting opioid medications (Table 1). The median daily opioid dose was 4.8 mg oral morphine equivalents (OME) with an interquartile range (IQR) of 0 to 14.7 mg. Sixty-six percent of patients used less than 10 mg OME daily whereas 11% used more than 50 mg OME daily (Figure 1). Among the short-acting opioids, acetaminophen-hydrocodone was the most commonly used medication (34% of patients) followed by immediate-release morphine (23%) and acetaminophen-codeine (20%) (Table 2). Extended-release morphine was used by 24% of the patients. Twelve patients (8.6%) were prescribed with nonsteroidal anti-inflammatory drugs (NSAIDs), and 16% used medications treating neuropathic pain. The Spearman correlation test with Bonferroni correction showed that the dose of opioid usage was significantly associated with the number of hospital admissions due to vaso-occlusive crisis (VOC) (p<0.0001) (Table 3). Hydroxyurea use, hemoglobin genotype, history of avascular necrosis (AVN) and 25-OHD levels did not correlate with opioid dose.

Summary: The doses and types of opioid medications used by adult SCD patients vary widely. The majority of patients use a relatively low dose (

organization: University of Illinois at Chicago

read more

Trusted Resources Home

Education & Research

People & Places

News & Events

Videos & Visuals

Community Center

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease

Related Content

Powered by

Trusted Resources Home

Education & Research

People & Places

News & Events

Videos & Visuals

Community Center

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease

Related Content

Powered by

Support for this site is provided by